

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S “CEFUROXIME AXETIL TABLETS”

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group’s “Cefuroxime Axetil Tablets (0.25g)” (the “**Drug**”) has been granted approval by the National Medical Products Administration of the People’s Republic of China for passing the consistency of quality and efficacy evaluation of generic drugs (the “**Consistency Evaluation**”).

Cefuroxime axetil is a cephalosporin antibiotic mainly used for the treatment of acute tonsillitis, pharyngitis, acute bacterial sinusitis, acute bacterial otitis media, acute paroxysm of chronic bronchitis, uncomplicated skin and skin soft tissue infection, uncomplicated urinary tract infection, early-stage Lyme disease (adults and children aged over 3 months), gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis.

Cefuroxime axetil tablet is one of the key anti-infective drugs of the Group. The passing of the Consistency Evaluation proves the consistency of the Drug with the originator drug in terms of quality and efficacy, indicating its availability as a clinical alternative for the originator drug and providing a medication option of good quality and competitive price for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 10 September 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.